Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
Overview of attention for article published in Clinical Cancer Research, March 2020
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (91st percentile)
-
High Attention Score compared to outputs of the same age and source (80th percentile)
Mentioned by
- news
- 2 news outlets
- 7 X users
- patent
- 4 patents
- guideline
- 1 clinical guideline source
Readers on
- mendeley
- 122 Mendeley